MARKET

AMTI

AMTI

Applied Molecular Transport Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.93
-0.43
-1.46%
Closed 16:00 07/29 EDT
OPEN
29.81
PREV CLOSE
29.36
HIGH
30.80
LOW
28.84
VOLUME
255.83K
TURNOVER
--
52 WEEK HIGH
78.22
52 WEEK LOW
20.50
MARKET CAP
908.42M
P/E (TTM)
-13.9040
1D
5D
1M
3M
1Y
5Y
Pacific Heights Asset Management Llc Buys Affirm Holdings Inc, Applied Molecular Transport Inc, ...
GuruFocus News · 6d ago
Burleson & Company, LLC Buys Enphase Energy Inc, Lordstown Motors Corp, The Home Depot Inc, ...
GuruFocus News · 07/22 18:38
Applied Molecular posts additional data from early-stage AMT-101 ulcerative colitis trial
Applied Molecular Transport (AMTI) announces additional Phase 1b data for oral AMT-101 in ulcerative colitis ((UC)) patients.The Phase 1b multiple ascending dose trial evaluated safety and was a randomized, placebo-controlled 3:1,
Seekingalpha · 07/09 12:30
Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO '21 Virtual Congress
Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology
GlobeNewswire · 07/09 12:00
Applied Molecular Transport Reports Positive Additional Data From Phase 1b Trial of AMT-101 to Treat UC Patients
MT Newswires · 07/09 08:44
Applied Molecular Transport slumps 5% as director sells shares
Applied Molecular Transport ([[AMTI]] -4.8%) stock drops 4.5% as director Helen Susan Kim sells 200,000 shares.Shares were priced between $43.3 to $46.47, worth approximately $8.7M.Director holds 600,000 shares post transaction.The stock has
Seekingalpha · 07/07 17:24
BRIEF-Applied Molecular Transport Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
reuters.com · 07/01 10:37
31 Stocks Moving In Monday's Mid-Day Session
Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share.
Benzinga · 06/21 16:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMTI. Analyze the recent business situations of Applied Molecular Transport Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMTI stock price target is 75.75 with a high estimate of 86.00 and a low estimate of 68.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 24.26M
% Owned: 77.27%
Shares Outstanding: 31.40M
TypeInstitutionsShares
Increased
31
1.25M
New
13
198.23K
Decreased
14
1.08M
Sold Out
4
77.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Helen Kim
Chief Executive Officer/Co-Founder/Director
Tahir Mahmood
Co-Founder/Chief Scientific Officer/Director
Randall Mrsny
Chief Financial Officer
Shawn Cross
Senior Vice President - Finance
Brandon Hants
Senior Vice President
Derek Maclean
Senior Vice President
Chuck Olson
Chief Technology Officer
Douglas Rich
Vice President
Andy Whitney
Other
Elizabeth Bhatt
Other
Bittoo Kanwar
Independent Director
Graham Cooper
Independent Director
David Lamond
Independent Director
Aaron VanDevender
No Data
  • All
  • Financials
  • Insiders
More
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform including its product candidate, AMT-101, an oral GI-selective rhIL-10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of rhIL-22. The Company’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics, with development-stage drugs.

Webull offers kinds of Applied Molecular Transport Inc. stock information, including NASDAQ:AMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMTI stock methods without spending real money on the virtual paper trading platform.